Mesoblast Limited (ASX: MSB, NASDAQ: MESO) will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026.

The event is scheduled for 6:30 pm EDT on Wednesday, August 26, and 8:30 am AEST on Thursday, August 27, 2026. Investors can access the live stream via the company’s designated webcast platform.

Webcast Access

Participants can join the session through the official link provided by the company. An archived version of the presentation will be available on the Investor page of the Mesoblast website following the event.

About Mesoblast

Mesoblast is a global leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. Its proprietary mesenchymal lineage cell therapy technology responds to inflammation by releasing anti-inflammatory factors that modulate the immune system.

Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients aged two months and older. The company is also developing Ryoncil for adults with SR-aGvHD and biologic-resistant inflammatory bowel disease.

Additionally, Mesoblast is advancing rexlemestrocel-L for heart failure and chronic low back pain. The firm has established commercial partnerships in Japan, Europe, and China.

Intellectual Property and Manufacturing

The company holds over 1,000 granted patents or patent applications covering cell compositions, manufacturing methods, and indications. This portfolio provides commercial protection through at least 2044 in major markets.

Mesoblast’s proprietary processes yield industrial-scale, cryopreserved, off-the-shelf cellular medicines with defined pharmaceutical release criteria, designed for global patient availability.

Mesoblast Limited (NASDAQ: MESO, ASX: MSB) has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The milestone marks a critical step toward potential regulatory approval for the allogeneic cellular medicine, targeting a market with a potential peak year revenue of greater than US$10 billion.

The trial enrolled 350 patients, an increase from the initial target of 300. The expansion was driven by strong demand from trial investigators to enroll their patients in the program. Participants were randomized to receive either an intra-discal injection of rexlemestrocel-L or a sham injection.

Trial Design and Endpoints

The primary endpoint of the MSB-DR004 trial aims to confirm durable pain reduction at 12 months following a single injection. This builds on earlier data from the MSB-DR003 trial, which successfully met this endpoint. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids.

Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for CLBP due to degenerative disc disease. This designation provides eligibility for priority review once the Biologics License Application (BLA) is filed.

Market Potential

Chronic low back pain caused by inflammation and degenerative disc disease affects over 7 million people in the U.S. alone. Mesoblast estimates the indication has a potential peak year revenue of greater than US$10 billion, even with single-digit market penetration.

Silviu Itescu, Chief Executive of Mesoblast, stated that completing treatment of 350 patients is a momentous milestone as the company counts down to the 12-month read-out.

What the Numbers Show

The increase in enrolled patients from 300 to 350 enhances the statistical power of the trial. With a larger sample size, the study is better positioned to demonstrate a significant treatment benefit of rexlemestrocel-L compared to controls, addressing the high prevalence of the condition which accounts for approximately 50% of opioid prescriptions in the U.S.